Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AdvaMed code tutorial

This article was originally published in The Gray Sheet

Executive Summary

Device trade association and Kaplan EduNeering launch an hour-long, online training course on AdvaMed's recently revised code of ethics on interactions with health care professionals, which, among other things, forbids device firms to provide entertainment, recreation and non-educational gifts of any value to physicians. The code takes effect July 1 (1"The Gray Sheet" Dec. 22, 2008, p. 5). Princeton, N.J.-based Kaplan EduNeering also provides online training and other tools to FDA's Office of Regulatory Affairs. The AdvaMed course is available for purchase at www.AdvaMed.org/MemberPortal/About/Code

You may also be interested in...



AdvaMed Code Of Ethics Make-Over: More Restrictions, More Guidance

AdvaMed's updated industry "code" for interacting with health care professionals forbids device firms to provide entertainment, recreation and non-educational gifts of any value, including pens, mugs and notepads

IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf

Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.

UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026

Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027513

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel